• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

SAR-CoV-2: More serious illness in younger people with new variant? Imperial College: Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: insights

sharon sanders

Editor-in-Chief & President
Report 42 - Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: insights from linking epidemiological and genetic data

Key info
Date:
31 December 2020


Authors:
Erik Volz[SUP]1[/SUP], Swapnil Mishra, Meera Chand, Jeffrey C. Barrett, Robert Johnson, Lily Geidelberg, Wes R Hinsley, Daniel J Laydon, Gavin Dabrera, ?ine O’Toole, Roberto Amato, Manon Ragonnet-Cronin, Ian Harrison, Ben Jackson, Cristina V. Ariani, Olivia Boyd, Nick Loman, John T McCrone, S?nia Gon?alves, David Jorgensen, Richard Myers, Verity Hill, David K. Jackson, Katy Gaythorpe, Natalie Groves, John Sillitoe, Dominic P. Kwiatkowski, COG-UK, Seth Flaxman, Oliver Ratmann, Samir Bhatt, Susan Hopkins, Axel Gandy, Andrew Rambaut, Neil M Ferguson[SUP]1[/SUP]

[SUP]1[/SUP]Correspondence:
e.volz@imperial.ac.uk
neil.ferguson@imperial.ac.uk

Download the full PDF for Report 42See all reports
WHO Collaborating Centre for Infectious Disease Modelling, MRC Centre for Global Infectious Disease Analysis, Abdul Latif Jameel Institute for Disease and Emergency Analytics (J-IDEA), in collaboration with the Department of Mathematics, Imperial College London, University of Edinburgh, Public Health England (PHE), the Wellcome Sanger Institute, University of Birmingham and the COVID-19 Genomics UK (COG-UK) Consortium+.

Summary


The SARS-CoV-2 lineage B.1.1.7, now designated Variant of Concern 202012/01 (VOC) by Public Health England, originated in the UK in late Summer to early Autumn 2020. We examine epidemiological evidence for this VOC having a transmission advantage from several perspectives. First, whole genome sequence data collected from community-based diagnostic testing provides an indication of changing prevalence of different genetic variants through time. Phylodynamic modelling additionally indicates that genetic diversity of this lineage has changed in a manner consistent with exponential growth. Second, we find that changes in VOC frequency inferred from genetic data correspond closely to changes inferred by S-gene target failures (SGTF) in community-based diagnostic PCR testing. Third, we examine growth trends in SGTF and non-SGTF case numbers at local area level across England, and show that the VOC has higher transmissibility than non-VOC lineages, even if the VOC has a different latent period or generation time. Available SGTF data indicate a shift in the age composition of reported cases, with a larger share of under 20 year olds among reported VOC than non-VOC cases.

https://www.imperial.ac.uk/mrc-globa...cov-2-variant/
 

MRC Centre for Global Infectious Disease Analysis

Dec 31, 2020
UPDATE #COVID19 new variant VOC202012/01 in England

VOC growing rapidly

Transmission advantage for VOC of 0.4 to 0.7 difference in reproduction number compared to non-VOC variant

VOC affecting a greater proportion of under 20s

Report https://imperial.ac.uk/mrc-global-infectious-disease-analysis/covid-19/report-42-sars-cov-2-variant/…


11m
Prof
@axel_gandy
on
@BBCRadio4
this morning speaking about the latest report on the new #SARSCoV2 variant of concern in England

https://bbc.co.uk/sounds/play/m000qnj6… (from 48:15)
@imperialcollege
Quote Tweet
vAvGCtjF_normal.jpeg

MRC Centre for Global Infectious Disease Analysis

Dec 31, 2020
UPDATE #COVID19 new variant VOC202012/01 in England

VOC growing rapidly

Transmission advantage for VOC of 0.4 to 0.7 difference in reproduction number compared to non-VOC variant

VOC affecting a greater proportion of under 20s

Report https://imperial.ac.uk/mrc-global-in...ariant/…
 
Back
Top Bottom